Dr. Paul is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1021 Morehead Medical Dr
Ste A
Charlotte, NC 28204Phone+1 980-442-2000Fax+1 919-843-9355
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2016 - 2019
University of North Carolina HospitalsResidency, Internal Medicine, 2013 - 2016
University of Miami Leonard M. Miller School of MedicineClass of 2013
Certifications & Licensure
NC State Medical License 2016 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT Start of enrollment: 2020 Jun 30
Publications & Presentations
PubMed
- MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma.Manisha Bhutani, Myra Robinson, David Foureau, Shebli Atrash, Barry A Paul
Blood Advances. 2024-11-22 - 1 citationsClinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial.Shambavi Richard, Alexander M Lesokhin, Barry Paul, Jonathan L Kaufman, Matthew Pianko
Nature Cancer. 2024-10-01 - Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma.Barry Paul, Faiz Anwer, Shahzad Raza, Aytaj Mammadzadeh, Bayan Khasawneh
Cancers. 2024-08-23
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
